Wu Zhuang

3.8k total citations · 1 hit paper
94 papers, 1.7k citations indexed

About

Wu Zhuang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Aerospace Engineering. According to data from OpenAlex, Wu Zhuang has authored 94 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 31 papers in Aerospace Engineering. Recurrent topics in Wu Zhuang's work include Lung Cancer Treatments and Mutations (48 papers), Advanced Antenna and Metasurface Technologies (31 papers) and Metamaterials and Metasurfaces Applications (27 papers). Wu Zhuang is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Advanced Antenna and Metasurface Technologies (31 papers) and Metamaterials and Metasurfaces Applications (27 papers). Wu Zhuang collaborates with scholars based in China, Taiwan and South Korea. Wu Zhuang's co-authors include Yanhong Zou, Xiqiao Chen, Zilong Zhang, Yang‐Yang Lv, Yaoyi He, C. Xu, Wenxian Wang, You‐cai Zhu, Nong Yang and Wei Li and has published in prestigious journals such as Journal of Clinical Oncology, Carbon and The Journal of Physical Chemistry C.

In The Last Decade

Wu Zhuang

89 papers receiving 1.7k citations

Hit Papers

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as F... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Jie Wang, Yanping Hu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wu Zhuang China 25 813 733 626 531 189 94 1.7k
Chuanhao Tang China 17 164 0.2× 97 0.1× 318 0.5× 288 0.5× 411 2.2× 61 1.1k
Bin Ke China 17 102 0.1× 280 0.4× 135 0.2× 204 0.4× 132 0.7× 46 914
Yueming Sun China 24 115 0.1× 33 0.0× 211 0.3× 110 0.2× 916 4.8× 64 1.5k
Cheng‐Lu Jiang China 14 92 0.1× 48 0.1× 90 0.1× 105 0.2× 158 0.8× 49 708
Yosuke Tamura Japan 19 17 0.0× 167 0.2× 225 0.4× 144 0.3× 112 0.6× 81 832
Yongbin Cao China 16 86 0.1× 19 0.0× 94 0.2× 203 0.4× 275 1.5× 34 985
Yukuan Huang China 13 69 0.1× 25 0.0× 147 0.2× 126 0.2× 241 1.3× 25 754
Hongyun Zhao China 21 22 0.0× 199 0.3× 252 0.4× 99 0.2× 1.0k 5.4× 35 2.0k
Xubin Li China 23 15 0.0× 86 0.1× 408 0.7× 304 0.6× 339 1.8× 65 1.6k
A. Diaz United States 13 310 0.4× 179 0.2× 17 0.0× 29 0.1× 151 0.8× 39 851

Countries citing papers authored by Wu Zhuang

Since Specialization
Citations

This map shows the geographic impact of Wu Zhuang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wu Zhuang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wu Zhuang more than expected).

Fields of papers citing papers by Wu Zhuang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wu Zhuang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wu Zhuang. The network helps show where Wu Zhuang may publish in the future.

Co-authorship network of co-authors of Wu Zhuang

This figure shows the co-authorship network connecting the top 25 collaborators of Wu Zhuang. A scholar is included among the top collaborators of Wu Zhuang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wu Zhuang. Wu Zhuang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fang, Xiang, Xiao Liu, Wu Zhuang, et al.. (2025). Functional Multispectral Camouflage Strategy Based on Flexible Transparent Metamaterial Compatible with Radiative Cooling. Laser & Photonics Review. 19(12). 2 indexed citations
2.
Yu, Jia, Caicun Zhou, Kai Wang, et al.. (2024). Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.. Journal of Clinical Oncology. 42(16_suppl). 8546–8546.
3.
Tan, Yonghong, Xiang Fang, Wu Zhuang, et al.. (2023). An ultra-broadband lightweight structural absorber with excellent absorption enhancement based on traditional carbon-based absorbents. Carbon. 214. 118269–118269. 10 indexed citations
4.
5.
6.
7.
Fang, Weijia, Cheng Wang, Jun Li, et al.. (2023). 2186P KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study. Annals of Oncology. 34. S1132–S1132. 3 indexed citations
8.
Yang, Yunpeng, Jie Min, Nong Yang, et al.. (2023). Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduction and Targeted Therapy. 8(1). 301–301. 15 indexed citations
9.
Zhuang, Wu, et al.. (2023). A broadband microwave absorber with properties optimized by an all-dielectric structure. Journal of Physics D Applied Physics. 56(50). 505003–505003. 1 indexed citations
10.
Chu, Tianqing, Jun Lü, Minghong Bi, et al.. (2021). Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biology and Medicine. 18(3). 816–824. 23 indexed citations
11.
Chen, Xiqiao, Wei Li, Wu Zhuang, Zilong Zhang, & Yanhong Zou. (2021). Origami-based microwave absorber with a reconfigurable bandwidth. Optics Letters. 46(6). 1349–1349. 28 indexed citations
12.
Wang, W., et al.. (2021). P88.02 SDC4-ROS1 Fusion as a Mechanism of Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology. 16(3). S686–S687. 1 indexed citations
13.
Li, Zhigang, Feng Ye, Dong Ma, et al.. (2021). First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.. Journal of Clinical Oncology. 39(15_suppl). 4049–4049. 16 indexed citations
14.
Xu, Cunshuan, Dawei Wang, Wu Zhuang, et al.. (2020). 415P Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing. Annals of Oncology. 31. S1404–S1404. 1 indexed citations
15.
Lei, Lei, Wenxian Wang, You‐cai Zhu, et al.. (2020). Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non- small cell lung cancer patients: a multicenter retrospective study. Translational Cancer Research. 9(10). 6039–6049. 2 indexed citations
16.
Zhang, Zilong, Xiqiao Chen, Wu Zhuang, et al.. (2019). Broadband metamaterial absorber for low-frequency microwave absorption in the S-band and C-band. Journal of Magnetism and Magnetic Materials. 497. 166075–166075. 75 indexed citations
17.
Wang, Wenxian, Hong Wang, Pei‐Hua Lu, et al.. (2019). Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. Journal of Translational Medicine. 17(1). 52–52. 28 indexed citations
18.
Xu, C., W. Wang, Wu Zhuang, et al.. (2018). P1.03-25 The Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology. 13(10). S521–S521. 1 indexed citations
19.
Zhu, You‐cai, Wenxian Wang, C. Xu, et al.. (2018). Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib. Journal of Thoracic Disease. 10(5). E359–E363. 13 indexed citations
20.
Li, Chao, Cheng Huang, Tony Mok, et al.. (2017). Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(10). 1536–1543. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chuanhao Tang Breakdown of academic impact, for papers by Bin Ke Breakdown of academic impact, for papers by Yueming Sun Breakdown of academic impact, for papers by Cheng‐Lu Jiang Breakdown of academic impact, for papers by Yosuke Tamura Breakdown of academic impact, for papers by Yongbin Cao Breakdown of academic impact, for papers by Yukuan Huang Breakdown of academic impact, for papers by Hongyun Zhao Breakdown of academic impact, for papers by Xubin Li Breakdown of academic impact, for papers by A. Diaz
Rankless by CCL
2026